Prot# ADMA-001: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial Evaluating the Safety and Efficacy of RI-001 in Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Severe RSV Illness